1. Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T, Yasugi T, Kozuma S, Taketani Y (2010) Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28:2810–2817
2. Adis Insight (2017a) Human papillomavirus vaccine recombinant quadrivalent—Serum Institute of India. Adis Insight.
http://adisinsight.springer.com/drugs/800047216
. Accessed 1 Aug 2017
3. Adis Insight (2017b) An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of bivalent human papillomavirus (types 16 L1 & 18 L1) vaccine of M/s Cadila Healthcare Ltd., India in healthy, adult, female, human subjects. Adis Insight.
http://adisinsight.springer.com/drugs/800040232
. Accessed 26 Aug 2016
4. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000) The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 74:11636–11641
5. Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG (2003) General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 41:2509–2514